Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review

Autor: Wynne Widiarti, Firas Farisi Alkaff, Alverina Cynthia Sukmajaya, David Nugraha
Rok vydání: 2021
Předmět:
Zdroj: Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 15:837-843
ISSN: 1871-4021
DOI: 10.1016/j.dsx.2021.04.005
Popis: Background and aims: Cardiovascular disease is one of the main contributors for the mortality in type 2 diabetes mellitus (T2DM) patients. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) had shown cardiovascular benefits which may be advantageous to reduce mortality in T2DM patients. This systematic review focused on analyzing the effects of GLP-1 RAs on cardiovascular outcomes. Methods: We conducted an extensive search through JSTOR, PubMed, Scopus, EBSCohost, and CENTRAL. All related studies assessing the use of GLP-1 RAs in T2DM patients from inception up to October 2020 were screened. Any cardioprotective properties as the outcomes were obtained. Results: A total of six studies (4 randomized, 2 observational) with a total of 182.205 patients were included in this review. The GLP-1 RAs used were either liraglutide or exenatide in combination with antihypertensive or antilipidemic drugs. All studies showed that GLP-1 RA significantly caused weight loss and improved cardiac functional capacity by increasing left ventricular ejection fraction and reducing end-systolic and end-diastolic left ventricle volume. GLP-1 RA also improved myocardial blood flow without affecting myocardial glucose uptake. However, GLP-1 RA failed to show its effect in reducing blood pressure and improving lipid profiles. Conclusions: Despite the limited number of studies, consistent data showed that GLP-1 RA has several cardioprotective properties. (C) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: